Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
The Oncologist
Chmielecki, Juliann J; Ross, Jeffrey S JS; Wang, Kai K; Frampton, Garrett M GM; Palmer, Gary A GA; Ali, Siraj M SM; Palma, Norma N; Morosini, Deborah D; Miller, Vincent A VA; Yelensky, Roman R; Lipson, Doron D; Stephens, Philip J PJ